



Corporate Overview

October 2026



Forward-looking statements

This presentation contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to our ability to maintain existing and obtain additional regulatory approvals of ZEVASKYN® and any future product candidates; our ability to successfully commercialize and market ZEVASKYN® and any future product candidates, if approved, and the timing of any commercialization and marketing efforts; our ability to manufacture sufficient batches of ZEVASKYN® to meet demand; our ability to manufacture ZEVASKYN® batches that meet certain product release specifications that were required by FDA at the time of BLA approval and implemented based on a limited clinical dataset; the FDA’s willingness to revise such release specifications to reflect real-world manufacturing experience; our ability to manufacture from provided biopsy material a ZEVASKYN® batch for which revenue may ultimately be recognized, which depends on such factors as qualified treatment centers obtaining biopsy samples from ZEVASKYN® patients of sufficient quality to act as starting material for manufacturing ZEVASKYN®, patient-to-patient variability in cell growth during the ZEVASKYN® manufacturing process, patient health deterioration in close proximity to ZEVASKYN® treatment such that treatment is no longer possible, and expiration of ZEVASKYN®’s 84-hour shelf-life before surgical application of ZEVASKYN® can be performed; our ability to activate additional qualified treatment centers to administer ZEVASKYN® on patients; the ability of qualified treatment centers to enroll patients for treatment or administer ZEVASKYN® on patients; our ability submit an investigational new drug application for ABO-701 and enroll patients in new clinical trials; our ability to access additional financial resources and/or our financial flexibility to reduce operating expenses if required; our ability to obtain additional equity funding from current or new stockholders; the potential impact of unpredicted changes in the structure and/or administration of the United States government or its agencies; our ability to out-license technology and/or other assets, deferring and/or eliminating planned expenditures, restructuring operations and/or reducing headcount, and sales of assets; the dilutive effect that raising additional funds by selling additional equity securities would have on the relative equity ownership of our existing investors, including under our existing at-the-market sale agreement; the outcome of any interactions with the FDA or other regulatory agencies relating to any of our products or product candidates; our ability to continue to secure and maintain regulatory designations for our product candidates; our ability to develop manufacturing capabilities compliant with current good manufacturing practices for our product candidates; our ability to manufacture cell and gene therapy products and produce an adequate product supply to support clinical trials and potentially future commercialization; the rate and degree of market acceptance of our product candidates for any indication once approved; our ability to meet our obligations contained in license agreements to which we are party; and macroeconomic uncertainty resulting from changes to U.S. trade policy, including current or future tariffs or other trade restrictions.

Pipeline of differentiated cell and gene therapies

zevaskyn™
(prademagene zamikeracel)
gene-modified cellular sheets


PSMA-SIR-T*
Advanced Prostate Cancer

UX111**
Sanfilippo syndrome type A (MPS IIIA)

TSHA-102***
Rett syndrome

Undisclosed (AAV204 capsid)****
Range of prevalent and rare retinal diseases

PARTNERED



* In-licensed in Q1 2026


Partners: **Ultragenyx Pharmaceutical Inc, ***Taysha Gene Therapies, Inc, **** Beacon Therapeutics (non-exclusive)

ZEVASKYN® foundation for Abeona's growth

Q2 2026 Highlights

- **Growing Qualified Treatment Center (QTC) network** across US, where 40% of the addressable US market has in-state access to a QTC
 - 100+ patients have been identified across QTCs and non-QTC physicians
 - Working toward streamlining long, unpredictable administrative steps from patient ID to treatment
- **High unmet need in RDEB with growing interest in ZEVASKYN:**
 - Only therapy to demonstrate multi-year wound healing in RDEB following a one-time application
 - Differentiated value proposition in the treatment landscape, where other approved products do not fully address patients' wound-healing needs
- **12 commercial treatments launch-to-date:** 1 in Q4'25; 3 in Q1'26; 5 in Q2, 3 in Q3-to date (as of Aug 13). Revenue recognized for 10 patients*
- **Robust launch foundation now in place** for long-term growth
 - Durable market opportunity insulated from traditional generic competition
- **\$146.8M in cash, cash equiv, short-term investments** (June 30, 2026)

Net Product Revenue (\$M)



Sequential Top-Line Growth:
Q2 net product revenue +31% Q/Q.

* One batch yielded fewer release-spec sheets than internal billing threshold. One batch failed a release identity assay, not related to safety or potency. Both patients received treatment, but revenue was not recognized.

RDEB is caused by lack of functional C7 protein, resulting in large, chronic wounds

- Rare and debilitating condition caused by mutations in both copies of *COL7A1* gene
- RDEB wounds can lead to serious life-threatening complications
 - Years of large painful wounds, itch and infection
 - 90% risk of developing squamous cell carcinoma (SCC) by age 55², systemic infection and sepsis
 - 76% likelihood of death by age 40³
- Lifelong burden on patients and caregivers

RDEB TREATMENT GOALS

- Provide multi-year durable wound healing
- Provide long-term pain and itch relief
- Reduce risk of SCC

>30%
of patient's
body wounded¹



zevaskyn[®]
(prademagene zamikeracel)
gene-modified cellular sheets

**The only gene therapy that
genetically modifies patient's own
skin cells to treat wounds in children
& adults with RDEB**


- **Single surgical treatment**
- **Extensive coverage across multiple wound areas**
- **Years of wound healing and pain relief in clinical studies**



Geovanna, a ZEVASKYN[®] patient at age 8


Up to 12 ZEVASKYN sheets can be applied in one surgical session

Two pea-sized
(8 mm) biopsies




Up to 12
ZEVASKYN
sheets

ZEVASKYN sheets can be **joined together** to treat larger **wounds** on patient's front, back, or sides, or used **individually** for smaller wounds



ADULT with RDEB

CHILD with RDEB



ZEVASKYN
cellular sheet

Example RDEB wounds before and after ZEVASKYN treatment

BEFORE

AFTER ZEVASKYN

Left thigh



BEFORE

AFTER ZEVASKYN

Left leg



Left torso




Right arm



Source: Phase 3 VITAL study patient; wounds scored as at least 75% healing at week 24; individual results vary
Wound healing scoring was Investigator-assessed per predefined criteria.



EB patients already travel significant distances for specialized care and have indicated willingness to travel for ZEVASKYN

Referral Catchment Areas For Key EB COEs (2022-2023)



- Roughly 40% of pts managed at EB COEs live out of state
- 70% of referrals come from 300 – 400 miles away

Expanding ZEVASKYN QTC network enhances patient access




Patient support hub

Abeona Assist™
Your partner in navigation and support

Personalized support when
you need it
(1-855-ABEONA-1)

ZEVASKYN patient journey




Example of wound healing from Phase 1/2a long term follow up

Upper Back

Patient before treatment




Patient after surgery



Patient during long term follow up – year 2



Patient at end of in-person long term follow up – year 5



All images shown are from the same patient; Individual results may vary.

- **Study Design:** Open label, single arm (no placebo/control wounds), single-center
 - Because the study did not include a control group or placebo for comparison, it was not designed to determine whether the observed effects were due to ZEVASKYN
- **Patient Population:** 7 patients with RDEB, 38 chronic wounds treated
- **Planned continued virtual follow up, up to 15 years**

Case study example of the longest patient follow up of 12 years from Phase 1/2a

Distal Right Forearm

Patient before treatment



Patient during long term follow up
– Year 1



Patient during long term follow up
– Year 6



Patient during long term follow up
– Year 12



All images shown are from the same patient; Individual results may vary.

- **Study Design:** Open label, single arm (no placebo/control wounds), single-center
 - Because the study did not include a control group or placebo for comparison, it was not designed to determine whether the observed effects were due to ZEVASKYN
- **Patient Population:** 7 patients with RDEB, 38 chronic wounds treated
- **Planned continued virtual follow up, up to 15 years**

Case study example of the longest patient follow up of 12 years from Phase 1/2a

Right Deltoid Shoulder

Patient before treatment



Patient during long term follow up
– Year 1



Patient during long term follow up
– Year 6



Patient during long term follow up
– Year 12



All images shown are from the same patient; Individual results may vary.

- **Study Design:** Open label, single arm (no placebo/control wounds), single-center
 - Because the study did not include a control group or placebo for comparison, it was not designed to determine whether the observed effects were due to ZEVASKYN
- **Patient Population:** 7 patients with RDEB, 38 chronic wounds treated
- **Planned continued virtual follow up, up to 15 years**

Examples of wound healing at 5 years for Phase 3 patients

Wound #: Location	Baseline Day -26 to Day -1	Month 6	Year 1	Year 2	Year 5
Subject # 1 Right Upper Arm					
Subject # 2 Left Leg, Anterior					
Subject # 3 Left Thigh, Lateral					

Individual results may vary

Significant U.S. commercial opportunity for ZEVASKYN

~1,300 U.S. DEB patients¹;
~750 RDEB ZEVASKYN-eligible patients

Anticipate average **2 treatment cycles** per patient
to cover impacted body areas (~**1,500 treatment opportunities**)

\$3.1M WAC per each treatment

Strong early payer coverage and reimbursement



Cash flow positive upon treating >3 patients per month*

1. ClaimsAnalysis 2024;


* Not including R&D spend on potential new pipeline programs

Leveraging cell therapy
core competencies
to advance a novel pipeline

PSMA SIR-T™ for Advanced Prostate Cancer



PSMA SIR-T™ (ABO-701) has the potential to unlock cell therapy for prostate cancer patients with a high unmet need



- PSMA is a **validated target in prostate cancer**, but CAR-Ts and other immunotherapies targeting PSMA have failed to deliver durable efficacy and acceptable safety profiles
- PSMA SIR-T™ is a radically **novel engineered T-cell technology** with the potential to unlock cell therapy in prostate cancer
- Global KOLs in prostate cancer are **eager to participate in clinical trials with PSMA SIR-T™**
- Abeona leadership in **advancing complex cell and gene therapies** from academia through commercialization and with **oncology experience**



- Advanced prostate cancer claims **>30,000 lives in the US annually**
- **High mortality** despite advances (e.g., combinations with androgen receptor pathway inhibitors and radioligand therapies)

Anchored by ZEVASKYN and unique capabilities to commercialize complex genetic medicines, Abeona is poised for growth

Significant support of ZEVASKYN from RDEB community and commercial launch on positive trajectory



\$11.4M net product revenue in Q2 2026, 31% quarter-over-quarter increase



Pipeline solid tumor oncology PSMA program represents a multi-billion-dollar opportunity

